Pharma Grade 3-(N-morpholino)propanesulfonic acid (MW 209.26 g/mol) is used as a functional buffer salt in oral and injectable drug product manufacturing where control of pH between 6.5 and 7.9 is required and where phosphate, citrate, or acetate systems show unacceptable drift, precipitation, or API incompatibility. The buffer exhibits a pKa of 7.20 at 25 °C and a reported ΔpKa/°C near −0.01 pH unit °C⁻¹. In lyophilized injectable formulations, the free acid and its sodium salt are combined to yield a 10–25 mM buffer system, with the free-acid-to-salt ratio calculated from the Henderson–Hasselbalch equation at 25 °C using a temperature-compensated electrode calibrated against buffer standards traceable to NIST or Ph.Eur. 2.2.3. A 10 mM MOPS system at pH 7.20 has a theoretical buffer capacity of approximately 5.8 mM/pH; this is acceptable for low-dose or moderate-strength injectable products but may be insufficient for high-dose acidic or basic APIs, which require additional buffer capacity or a higher concentration. In cycle development, the filled solution is frozen on a lyophilizer shelf at −40 °C to −50 °C, annealed at −20 °C for 2–4 h when mannitol is present, and primary-dried at chamber pressure 50–100 mTorr with a shelf ramp of 0.5–1.0 °C/min. Differential scanning calorimetry and freeze-drying microscopy identify the critical formulation temperature; MOPS-containing amorphous phases may concentrate during freezing and shift ionic strength locally, so reconstituted osmolality is confirmed by USP <785> and pH by USP <791>. The final lyophilized cake is controlled to moisture not more than 1.0% by Karl Fischer titration USP <921>, reconstitution time not more than 2 min at 20–25 °C, and particulate matter limits of USP <788>. Because MOPS provides no bulking function, 3–5% w/v mannitol or trehalose is added as a crystalline scaffold; the buffer is not a substitute for a bulking agent. Processing and filling are conducted under 21 CFR 210/211 and EU GMP Annex 1 for aseptic operations. Strong oxidizing agents, peroxides, and hypochlorite residues from line sanitization are incompatible with the morpholine ring unless forced-degradation studies under ICH Q1B demonstrate acceptable stability.

Does Aqueous Granulation Fluid Buffering with MOPS Alter the Dissolution Profile of Acid-Labile Oral Tablets?

When MOPS is incorporated into the granulation fluid at 0.5–2.0% w/w of the final granule mass, it functions as an intragranular pH modifier rather than a bulk dissolution buffer. The granulation fluid is prepared by dissolving the buffer salt in purified water at 20–25 °C, adjusting pH to 7.0–7.4 with 1 M NaOH or 1 M HCl, and passing the solution through a 40–100 μm screen before addition to the high-shear mixer. Dry-blend ingredients are pre-mixed for 3–5 min at low impeller speed; the buffered liquid is then added at 15–30% w/w of the dry blend over 2–5 min. Wet massing continues until torque or power draw stabilizes, usually 1–3 min after complete fluid addition. The wet granules are dried in a fluid-bed dryer with inlet air temperature 60–70 °C and product temperature 35–45 °C until loss on drying reaches 1.5–2.5% w/w. Dried granules are milled through a 0.8–1.2 mm screen and compressed on a rotary tablet press with compression force adjusted to produce hardness 80–120 N and friability below 1.0% according to USP <1216>. Tablet disintegration is controlled by USP <701> with a limit of not more than 15 min, and single-point dissolution is tested by USP <711> at Q=80% in 30 min using the registered dissolution medium. The buffer may reduce free moisture availability at the API-binder interface and alter dissolution in a formulation-specific manner; published data for this specific configuration is limited, so multi-batch evaluation is required. If the free acid form is used instead of the sodium salt, handling in areas above 60% RH should be avoided unless the material is pre-dried and sieved under controlled humidity not exceeding 45% RH. MOPS does not act as a binder, disintegrant, or lubricant; those functional excipients must be selected independently.

Hard-shell capsule liquid fills containing pH-sensitive APIs in aqueous glycerol or PEG-water matrices are buffered with MOPS to maintain bulk fill pH between 7.0 and 7.4 during holding, capsule filling, and storage. The buffer is pre-dissolved in the water phase at 0.5–1.0% w/w of total fill mass because the sulfonic acid salt has poor solubility in pure PEG 400 and glycerol; a separate water-glycerol phase is therefore prepared at 40–50 °C and cooled to 25 °C before mixing with API and hydrophilic film-forming or viscosity-modifying polymers. Fill-matrix viscosity is maintained below 1000 mPa·s at 40 °C to permit accurate dosing on capsule-filling machines with piston or peristaltic fill systems. Moisture content of the fill is controlled below 5.0% w/w to prevent shell softening, brittleness, or deformation, and finished capsules are conditioned at 20–25 °C and 35–45% RH until overwrapping. Capsule shells are tested for disintegration and dissolution using USP <2040> and USP <711> where applicable. Fill pH is measured by direct electrode or after dilution into purified water under USP <791>; a drift greater than ±0.2 pH units after 72 h at 40 °C indicates insufficient buffer capacity or incompatibility between the fill vehicle and shell components. MOPS does not provide antimicrobial preservation; formulations with water activity above 0.6 require a preservative system per USP <51> unless the package is unit-dose and package integrity prevents microbial ingress. The fill pH is not a substitute for enteric coating, and MOPS does not confer acid resistance in the stomach.

Low Endotoxin Load and Conductivity Drift in Continuous Infusion Formulations

In continuous intravenous infusion products, MOPS is used at 5–15 mM to maintain pH 7.3–7.5 without contributing excessive ionic load. The solution is compounded in a stainless-steel or high-density polyethylene vessel with Water for Injection at 20–25 °C, and the free acid is neutralized with 1 M NaOH to the target pH before addition of sodium chloride or dextrose. Osmolality is adjusted to 280–320 mOsm/kg per USP <785>, and conductivity is monitored at 25 °C as an in-process indicator of buffer concentration; a 10 mM MOPS sodium salt solution contributes conductivity in the low millisiemens range, but the exact value must be established on the specific batch because trace counter-ions differ. Terminal sterilization at 121 °C for 15 min may be used only after thermal-stability studies demonstrate pH shift not more than 0.2 pH units and assay loss not more than 2.0%; the morpholine ring can undergo oxidation catalyzed by trace metal ions, so a chelating agent may be required if elemental impurities approach ICH Q3D limits. Filling is performed on blow-fill-seal or form-fill-seal lines with in-line pH and conductivity sensors, and the final container is inspected for particulate matter per USP <788>. Cover closure and tubing compatibility studies follow USP <661.1> and <661.2> because the sulfonate group may extract leachable cations or amines from elastomeric gaskets under heat. MOPS is not a tonicity agent and is not a substitute for sodium chloride or dextrose; the buffer contributes to osmolality and must be included in the final formula. Avoid terminal sterilization in flexible PVC containers unless the specific bag material is validated, because heat and pH stress may increase leachable load.

Prefilled syringe and cartridge presentations require low endotoxin burden, low subvisible particle counts, and stable pH in a small-volume parenteral vehicle. MOPS is used at 10 mM with pH 7.2±0.1 at 25 °C in Water for Injection, often with 0.5–1.0% w/w sodium chloride or isotonic dextrose. The solution is sterile-filtered through a 0.22 μm sterilizing-grade membrane; polyvinylidene fluoride and polyethersulfone filters are generally suitable, but filter-binding studies are required because the zwitterionic buffer may alter surface charge and affect membrane flux at low temperature. Filling occurs under grade A conditions within an isolator or restricted access barrier system, with environmental monitoring per ISO 14644-1 and EU GMP Annex 1. Subvisible particulate matter is controlled to USP <788> limits: not more than 6000 particles per container at ≥10 μm and not more than 600 particles per container at ≥25 μm. Endotoxin limits are set at <0.25 EU/mL unless the approved labeling specifies a higher limit for a particular dose, tested by USP <85>. The temperature coefficient of MOPS is approximately −0.01 pH unit °C⁻¹; therefore, pH measured at 2–8 °C during filling may be up to 0.2–0.3 pH units higher than at 25 °C, and the release specification must state the measurement temperature. Silicone oil from glass barrel lubrication and tungsten residues from needle formation should be assessed because they can generate particle formation or catalyze oxidative degradation of the morpholine ring; published data for this specific configuration is limited. The buffer is not a surfactant and does not reduce interfacial aggregation of biologics or synthetic peptides.

When Buffer Migration into Enteric Coating Layers Threatens Acid Resistance of Drug-Layered Pellets

Multi-particulate dosage forms using MOPS in the drug layer or seal layer require a barrier subcoat because the water-soluble buffer can migrate into enteric polymer films during curing and reduce acid resistance. Drug-layered pellets are produced in a Wurster column or rotor granulator by spraying a pH-adjusted dispersion containing 1–3% w/w MOPS onto sugar spheres or microcrystalline cellulose cores. The spray suspension is prepared at 20–25 °C and kept at pH 7.0–7.4 to limit API hydrolysis during spraying; inlet air temperature is set to 60–70 °C, and product temperature is controlled at 35–45 °C. Spray rate is adjusted to maintain surface moisture balance without agglomeration, typically 5–10 g/min per kg of core material in a laboratory-scale Wurster coater depending on fluid bed capacity and airflow. After drug layering, a protective subcoat such as hydroxypropyl methylcellulose with 1–2% w/w talc or glycerol monostearate is applied before enteric coating with methacrylic acid-ethyl acrylate copolymer dispersion. Enteric-coated pellets are filled into hard capsules and tested by two-stage dissolution per USP <711>; acid-stage exposure in 0.1 N HCl for 2 h permits not more than 10% release, followed by buffer-stage release of not less than 80% in 30 min at pH 6.8. Enteric film curing, typically 30–40 °C at 50–60% RH for 2–4 h, must be verified because MOPS migration into the enteric layer can plastify or destabilize the film; failure is indicated by increased acid-stage release and visible film roughness under scanning electron microscopy. The buffer is not an enteric polymer and does not confer acid resistance by itself. Published data for MOPS migration kinetics in methacrylic acid copolymer films is limited, so a specific barrier-layer thickness and cure cycle must be developed for each multi-particulate formulation.

Dry granules for oral suspension are buffered with MOPS to stabilize the reconstituted vehicle at pH 7.0–7.5 for the labeled in-use period, often 7–14 days under refrigeration. The buffer is incorporated at 1–3% w/w of the dry granule mass by wet granulation or dry blending with a lactose or mannitol-based filler system. Granules are dried to moisture below 2.0% w/w and filled into sachets or bottles; fill weight is controlled to meet USP <905> uniformity of dosage units if the product is presented as a unit-dose sachet. Upon reconstitution with the specified volume of purified water at 20–25 °C, the suspension is shaken until dispersed and the pH is checked with a calibrated electrode per USP <791>; a drop of more than 0.2 pH units from the development value after storage indicates moisture ingress or buffer degradation. A suspending system such as xanthan gum, microcrystalline cellulose and sodium carboxymethylcellulose, or hydroxyethylcellulose is required because MOPS has no suspending capability. Preservative requirement is assessed by USP <51> when the in-use period exceeds 24 h and the product is not a single-use container. The reconstituted suspension should be stored at 2–8 °C; at higher temperatures buffer capacity remains, but microbial growth risk increases and pH drift may occur in poorly sealed containers. Dry granules containing MOPS should be protected from humidity above 60% RH during storage and sachet filling, because moisture uptake can accelerate particle agglomeration and reduce flow through dosing equipment.